

Specifications:

Balloon Diameter (mm)	Balloon length (mm)					
	10	15	17	20	26	30
2.50	G2.50-10	G2.50-15	G2.50-17	G2.50-20	G2.50-26	G2.50-30
2.75	G2.75-10	G2.75-15	G2.75-17	G2.75-20	G2.75-26	G2.75-30
3.00	G3.00-10	G3.00-15	G3.00-17	G3.00-20	G3.00-26	G3.00-30
3.50	G3.50-10	G3.50-15	G3.50-17	G3.50-20	G3.50-26	G3.50-30
4.00	G4.00-10	G4.00-15	G4.00-17	G4.00-20	G4.00-26	G4.00-30

Compliance:

Pressure (atm)	Balloon Diameter (mm)				
	2.50	2.75	3.00	3.50	4.00
2	2.36	2.59	2.82	3.29	3.77
4	2.43	2.67	2.91	3.39	3.89
6 (NP)	2.50	2.75	3.00	3.50	4.00
8	2.57	2.83	3.09	3.61	4.11
10	2.64	2.91	3.18	3.71	4.23
12	2.71	2.98	3.27	3.82	4.34
14 (RBP)	2.78	2.06	3.36	3.92	4.45
16	2.85	2.14	3.45	4.03	4.57
18	2.92	2.22	3.54	4.14	4.68



This product should be used by physicians. Please read the product manual carefully before use to understand the indications, contraindications, instructions, precautions and possible complications.
© Zhejiang Barty Medical Technology Co., Ltd. All rights reserved.

Zhejiang Barty Medical Technology Co.,Ltd
Add : Room 101, 201, 301, Building 26, Yinhai Technology Innovation Center, Xiasha Street,
Qiantang District,310018 Hangzhou City, Zhejiang Province, China
Tel: +86 0571-88373719
Fax:+86 0571-88373716
Website: www.barty-medical.com Email:info@bartymedical.com




A safer choice
Drug coated balloon catheter
with NO EXCIPIENT



Excipient-free nano grade acicular coating

Brand new coating technique
Paclitaxel only, no excipient.

Coating under SEM



No excipient

Effectively improve the biocompatibility of the coating and avoid vascular inflammatory reactions and allergic reactions caused by the excipients.

Nano grade acicular paclitaxel


Acicular paclitaxel particle directly transfers to target blood vessel wall, then to the subintimal membrane to form a drug micro-reservoir to maintain effective drug concentration for a long time and to prevent restenosis.

Ultrasonic atomization spraying technique

Ensure the uniformity of drug particles in sizing. The average particle size is less than 300nm, which reduces drug loss during DCB delivery and reduces the risk of distal microvascular embolism caused by the shedding of large-diameter coating particles.


Semi-compliant
balloon catheter

- Optimized crossing profile
- Enhanced pushability
- Outstanding crossability




Excipient-free drug solution


Competitive crossing profile



The effective paclitaxel level in the tissue can be sustained for up to 28 days. Excessive proliferation of the endometrium can be continuously inhibited.



Clinical study



Clinical follow-up of 211 patients with in-stent restenosis

	Flowty™	SeQuent® Please	Pvalue
Pretreatment target lesion stenosis (%)	67.65±16.56	66.76±13.78	0.657
Target lesion in-segment late lumen loss at 9 month follow-up (mm)	0.35±0.42	0.38±0.45	0.549
Target lesion in-segment restenosis at 9-month follow-up (%)	10.34	10.58	0.858
Target lesion failure rate at 12-month follow-up (%)	15.24	13.21	0.673
Incidence of thrombotic events at 12-month follow-up (%)	0.95	0.94	0.957

CONCLUSION

Flowty shows great safety and efficacy performance. The results of Flowty and control group were similar without statistical difference.